Benson Outpatient Treatment Center | |
611 W Union St Benson AZ 85602-6718 | |
(520) 586-6177 | |
Not Available |
Full Name | Benson Outpatient Treatment Center |
---|---|
Speciality | Community/Behavioral Health |
Location | 611 W Union St, Benson, Arizona |
Authorized Official Name and Position | Estella Hernandez (CONTRACTS & CREDENTIALING ADMIN) |
Authorized Official Contact | 5208385513 |
Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
Mailing Address | Practice Location Address |
---|---|
Benson Outpatient Treatment Center 611 W Union St Benson AZ 85602-6718 Ph: () - | Benson Outpatient Treatment Center 611 W Union St Benson AZ 85602-6718 Ph: (520) 586-6177 |
NPI Number | 1760830137 |
---|---|
Provider Enumeration Date | 05/26/2016 |
Last Update Date | 06/08/2022 |
Certification Date | 06/08/2022 |
Medicare PECOS PAC ID | 2860488368 |
---|---|
Medicare Enrollment ID | O20040421000934 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Identifier | Type | State | Issuer |
---|---|---|---|
1760830137 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
251S00000X | Community/behavioral Health | BH4804 (Arizona) | Primary |
Provider Name | Judith M Johnson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1962458182 PECOS PAC ID: 6406769207 Enrollment ID: I20031107000474 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | John K Ekman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1194722256 PECOS PAC ID: 4183695281 Enrollment ID: I20040803000744 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Vinod B Patel |
---|---|
Provider Type | Practitioner - Sleep Medicine |
Provider Identifiers | NPI Number: 1821054503 PECOS PAC ID: 9234103235 Enrollment ID: I20040825000249 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Georgina L Fiscus |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1780621862 PECOS PAC ID: 3173599537 Enrollment ID: I20040907001146 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Veeraiah C Karumanchi |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1467456707 PECOS PAC ID: 8729032693 Enrollment ID: I20050303000926 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Dmitry V Listengarten |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1669433173 PECOS PAC ID: 4486680931 Enrollment ID: I20050715000218 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Mohamed I Ramadan |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1225025984 PECOS PAC ID: 4183657034 Enrollment ID: I20050913000165 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Jane Ackerley |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1588868921 PECOS PAC ID: 4880761055 Enrollment ID: I20080930000596 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Chad Rubin |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1548256142 PECOS PAC ID: 5597822288 Enrollment ID: I20090325000128 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Constance L Slay |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1396919346 PECOS PAC ID: 5294882940 Enrollment ID: I20090415000203 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Mary K Fuller-fougerousse |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1336479906 PECOS PAC ID: 9830232487 Enrollment ID: I20100204000088 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Mary J Maymana |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1457558868 PECOS PAC ID: 3577759885 Enrollment ID: I20101129001059 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Eric A Hegybeli |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1487879342 PECOS PAC ID: 2668658527 Enrollment ID: I20110511000269 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Steven M Diez De Pinos |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1063502201 PECOS PAC ID: 2264699925 Enrollment ID: I20120208000066 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Linda M Banziger |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1467695726 PECOS PAC ID: 6800925371 Enrollment ID: I20120302000660 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | William Adamas-rappaport |
---|---|
Provider Type | Practitioner - Pediatric Medicine |
Provider Identifiers | NPI Number: 1134213762 PECOS PAC ID: 3577722313 Enrollment ID: I20120314000140 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Daniel D Hammond |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1518116839 PECOS PAC ID: 2961541495 Enrollment ID: I20140820000525 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Dorothy Deette Burke |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1497883169 PECOS PAC ID: 4587757042 Enrollment ID: I20140903001953 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Maryam H Lateef |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1477533610 PECOS PAC ID: 3577475888 Enrollment ID: I20141023000369 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Nirva Jean-baptiste |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1407279771 PECOS PAC ID: 3577887553 Enrollment ID: I20150122000480 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Sharon A Stokes |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1144376070 PECOS PAC ID: 5991014581 Enrollment ID: I20151021003327 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Catherine M Etori |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255722633 PECOS PAC ID: 6103145974 Enrollment ID: I20151106000597 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Karen Shelton |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1164836565 PECOS PAC ID: 3375843360 Enrollment ID: I20151123002666 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Rodric D Falcon |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1063785350 PECOS PAC ID: 9234367400 Enrollment ID: I20160323001111 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Sarah Manco |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1396907598 PECOS PAC ID: 3678736238 Enrollment ID: I20160429000909 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Brett Lee Wadsworth |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1649727249 PECOS PAC ID: 6709168743 Enrollment ID: I20170126001961 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Kelleen Stiles |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1437468840 PECOS PAC ID: 9638453160 Enrollment ID: I20170301002060 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Michael D Worley |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1548704125 PECOS PAC ID: 4880962687 Enrollment ID: I20170620002766 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Sonia J Shoup |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1861672081 PECOS PAC ID: 8527286210 Enrollment ID: I20171003007562 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Erkan Caygoz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1356868160 PECOS PAC ID: 0547528218 Enrollment ID: I20171229002261 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Jillian Eve Young |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1134614324 PECOS PAC ID: 8820347685 Enrollment ID: I20180828001372 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Tolulope A Dada |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1124418728 PECOS PAC ID: 0143548586 Enrollment ID: I20181015000551 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Tera K Waldroup |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1710250055 PECOS PAC ID: 7719204320 Enrollment ID: I20181016001341 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Marie A Smith |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1619219375 PECOS PAC ID: 2668613811 Enrollment ID: I20181105002586 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Jennifer Neiss |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1518588763 PECOS PAC ID: 5991126609 Enrollment ID: I20200605000292 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Anton Dragonetti |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1972091221 PECOS PAC ID: 8224393640 Enrollment ID: I20210909003132 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Traci Burks |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1528171899 PECOS PAC ID: 7012310063 Enrollment ID: I20220120002473 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Daniel J Arteago |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1235563909 PECOS PAC ID: 3274929260 Enrollment ID: I20220330002087 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Provider Name | Patricia Hoffman |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1114994050 PECOS PAC ID: 9335583624 Enrollment ID: I20240214002478 |
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
News Archive
Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.
Stunning scientific images of blood, brain, bacteria, viruses and more, enlarged by as much as 50,000 times, are on display in an exhibit called "Life: Magnified," on view through November 2014 at Washington Dulles International Airport's Gateway Gallery.
High technology that will enhance the ability of biologists to conduct cutting-edge research has been opened at the Research School of Biological Sciences (RSBS) at the Australian National University.
On the 13th of September 2017, a U.S. Food and Drug Administration (FDA) advisory panel has voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline's Shingrix is on its way to FDA approval.
› Verified 7 days ago
Nazcare, Inc. - B.e.s.t. Wellness Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 176 S Central Ave, Benson, AZ 85602 Phone: 928-442-9205 Fax: 602-535-3230 | |
Caring Connections For Special Needs, Llc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 870 W 4th St, Benson, AZ 85602 Phone: 520-686-9436 | |
Southeastern Arizona Behavioral Health Services, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 611 W Union St, Benson, AZ 85602 Phone: 520-586-0800 Fax: 520-586-0116 | |
Caring Connections For Special Needs, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 505 E 5th St, Benson, AZ 85602 Phone: 520-586-2070 Fax: 480-287-8448 | |
Lazy Horse Ranch Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 714 N Madison Ave, Benson, AZ 85602 Phone: 520-826-2206 | |
Freedom Counseling Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 880 W 4th Street, Benson, AZ 85602 Phone: 520-720-6488 Fax: 520-720-6486 |